Palatin Technologies (PTN) News Today $1.10 +0.04 (+3.77%) As of 04:10 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Palatin Technologies (NYSEAMERICAN:PTN) Shares Pass Above 200 Day Moving Average - Should You Sell?January 16, 2025 | americanbankingnews.comPalatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic NephropathyDecember 19, 2024 | finanznachrichten.dePalatin Announces Positive Results In Phase IIb Study Of Bremelanotide In Diabetic NephropathyDecember 19, 2024 | markets.businessinsider.comPalatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic NephropathyDecember 19, 2024 | prnewswire.comPalatin Announces Exercise of Warrants for Approximately $3.4 Million Gross ProceedsDecember 16, 2024 | prnewswire.comPalatin completes patient enrollment in Phase 2 study of PL8177November 25, 2024 | markets.businessinsider.comBuy Rating for Palatin Technologies: Promising Pipeline and Strategic Initiatives in Obesity TreatmentNovember 25, 2024 | markets.businessinsider.comPalatin Completes Patient Enrollment In Phase 2 Study Of PL8177 In Ulcerative Colitis, Shares Up 16%November 25, 2024 | markets.businessinsider.comPalatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative ColitisNovember 25, 2024 | prnewswire.comPalatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ...November 16, 2024 | finance.yahoo.comPalatin Technologies Shifts Focus to Obesity TreatmentsNovember 15, 2024 | markets.businessinsider.comPalatin Technologies: Strategic Focus on Obesity and Diversified Pipeline Justifies Buy RatingNovember 14, 2024 | markets.businessinsider.comPalatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call TranscriptNovember 14, 2024 | seekingalpha.comPalatin Technologies Inc. Loss At -$7.82 Mln In Q1November 14, 2024 | markets.businessinsider.comPalatin Reports First Quarter Fiscal Year 2025 Operating/Financial ResultsNovember 14, 2024 | prnewswire.comPalatin Technologies Q1 2025 Earnings PreviewNovember 13, 2024 | msn.comPalatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024November 8, 2024 | prnewswire.comPalatin to report data from MC4R selective PL7737 obesity programNovember 5, 2024 | markets.businessinsider.comPalatin Technologies’ PL7737: A Promising Obesity Treatment Highlighted by New Preclinical DataNovember 5, 2024 | markets.businessinsider.comPalatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024November 4, 2024 | prnewswire.comPalatin Technologies: Promising Pipeline Advances and Positive Trial Developments Drive Buy RatingOctober 31, 2024 | markets.businessinsider.comPalatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of ObesityOctober 31, 2024 | prnewswire.comInflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics SymposiumOctober 24, 2024 | prnewswire.comPalatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics SymposiumOctober 23, 2024 | prnewswire.comPalatin Receives Notice of Non-Compliance from NYSE AmericanOctober 7, 2024 | prnewswire.comPalatin Technologies, Inc. (AMEX:PTN) Q4 2024 Earnings Call TranscriptOctober 2, 2024 | msn.comPalatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ...October 2, 2024 | finance.yahoo.comBuy Rating Affirmed: Palatin Technologies’ Strong Earnings and Promising Pipeline Signal Growth OpportunitiesOctober 1, 2024 | markets.businessinsider.comPalatin Technologies Inc. Q4 Loss NarrowsOctober 1, 2024 | markets.businessinsider.comPalatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated MilestonesOctober 1, 2024 | prnewswire.comPalatin Technologies Inc (PTN) Q4 2024 Earnings Report Preview: What To ExpectSeptember 30, 2024 | finance.yahoo.comPalatin Techs (AMEX:PTN) Stock, Short Interest ReportSeptember 27, 2024 | benzinga.comPalatin to Report Fourth Quarter and Fiscal Year End 2024 ResultsSeptember 26, 2024 | prnewswire.comPalatin (PTN) Earnings Dates & ReportsSeptember 13, 2024 | investing.comPalatin advances on multiple clinical programs, eyes key milestonesSeptember 11, 2024 | uk.investing.comPalatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated MilestonesSeptember 9, 2024 | prnewswire.com0KF3.IL,0P0001H3SZ,0 (0KF3.IL)August 31, 2024 | ca.finance.yahoo.comBuy Rating Affirmed for Palatin Technologies Amidst Promising Drug Developments and Clear FDA PathwaysAugust 29, 2024 | markets.businessinsider.comFDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)August 28, 2024 | prnewswire.comPositive Buy Rating for Palatin Technologies Based on Promising Obesity and ED Clinical TrialsAugust 23, 2024 | markets.businessinsider.comFirst Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of ObesityAugust 22, 2024 | prnewswire.comPTN Sep 2024 2.500 callAugust 17, 2024 | ca.finance.yahoo.comPalatin Technologies Inc (PTN.BE)July 19, 2024 | finance.yahoo.comPalatin Announces Exercise of Warrants for Approximately $6.1 Million Gross ProceedsJune 21, 2024 | prnewswire.comPalatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)June 20, 2024 | prnewswire.comPalatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of ObesityJune 12, 2024 | prnewswire.comPalatin Technologies Upgraded to Buy: What Does It Mean for the Stock?May 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN) and Prestige Consumer Healthcare (PBH)May 16, 2024 | markets.businessinsider.comPalatin Technologies, Inc. (AMEX:PTN) Q3 2024 Earnings Call TranscriptMay 16, 2024 | msn.comQ3 2024 Palatin Technologies Inc Earnings CallMay 16, 2024 | finance.yahoo.com Get Palatin Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter. Email Address PTN Media Mentions By Week PTN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTN News Sentiment▼0.750.63▲Average Medical News Sentiment PTN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTN Articles This Week▼12▲PTN Articles Average Week Get Palatin Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for PTN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ADVM News SKYE News BLUE News ADAG News GNLX News EPRX News CUE News IPSC News VTGN News APLT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:PTN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palatin Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palatin Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
